**Obesity and Inflammation**

benzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol transferase (DGAT) 1

[98] Tomimoto D, Okuma C, Ishii Y, Kobayashi A, Ohta T, Kakutani M, et al. JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice. J Pharmacol Sci 2015;129(1):51–

[99] Ables GP1, Yang KJ, Vogel S, Hernandez-Ono A, Yu S, Yuen JJ, et al. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 2012;53(11):2364–79.

[100] Senior JR, Isselbacher KJ. Direct esterification of monoglycerides with palmityl coenzyme a by intestinal epithelial subcellular fractions. J Biol Chem 1962;237:1454–9.

[101] Yen CL, Farese RV Jr. MGAT2, a monoacylglycerol acyltransferase expressed in the

[102] Yen CL, Stone SJ, Cases S, Zhou P, Farese RV Jr. Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase. Proc Natl Acad Sci U S A 2002;99(13):

[103] Cao J, Cheng L, Shi Y. Catalytic properties of MGAT3, a putative triacylgycerol

[104] Tsuchida T, Fukuda S, Aoyama H, Taniuchi N, Ishihara T, Ohashi N, et al. MGAT2 deficiency ameliorates high-fat diet-induced obesity and insulin resistance by inhibit-

[105] Okawa M, Fujii K, Ohbuchi K, Okumoto M, Aragane K, Sato H, et al. Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion. Biochem Biophys

[106] Yen CL, Cheong ML, Grueter C, Zhou P, Moriwaki J, Wong JS, et al. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from

[107] Gao Y, Nelson DW, Banh T, Yen MI, Yen CL. Intestine-specific expression of MOGAT2 partially restores metabolic efficiency in Mogat2-deficient mice. J Lipid Res 2013;54(6):

[108] Nelson DW, Gao Y, Yen MI, Yen CL. Intestine-specific deletion of acyl-CoA:monoacylglycerol acyltransferase (MGAT) 2 protects mice from diet-induced obesity and glucose

[109] Okuma C, Ohta T, Ito M, Tadaki H, Oda T, Kume S, et al. Intrajejunal infusion of 2 monoacylglycerol reduced food intake without inducing diarrhea in rats. J Pharmacol

metabolic disorders induced by high-fat feeding. Nat Med 2009;15(4):442–6.

ing intestinal fat absorption in mice. Lipids Health Dis 2012;11:75.

inhibitor. Biol Pharm Bull 2015;38(2):263–9.

70 Adiposity - Omics and Molecular Understanding

small intestine. J Biol Chem 2003;278(20):18532–7.

synthase. J Lipid Res 2007;48(3):583–91.

Res Commun 2009;390(3):377–81.

intolerance. J Biol Chem 2014;289(25):17338–49.

8.

8512–7.

1644–52.

Sci 2016;130(2):136–8.

#### **Obesity and Its Influence on Mediators of Inflammation: Clinical Relevance of C-Reactive Protein in Obese Subjects Obesity and Its Influence on Mediators of Inflammation: Clinical Relevance of C-Reactive Protein in Obese Subjects**

Emilio González-Jiménez Emilio González-Jiménez

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/64881

#### **Abstract**

The rising prevalence of overweight and obesity in the world has been described as a global pandemic, with marked variations across countries in the levels and trends in overweight and obesity with distinct regional patterns. Concern about the health risks associated with rising obesity has become nearly universal. In this chapter, a systematic review that was conducted in four databases (Web of Science, MEDLINE, Scopus, CINAHL), using the MeSH terms [obesity, inflammation, disease management, C-reactive protein (CRP)] is presented. Based on the above, the aims of this work are to provide information on the relationship between obesity and circulating levels of CRP, to describe the basic chemical structure and functions, and to analyze its clinical usefulness in obese patients. The available scientific evidence justifies the need to include determining the values of high-sensitivity C-reactive protein (hs-CRP) among clinical screening tests on obese subjects to evaluate the cardiovascular risk, among other risks.

**Keywords:** obesity, inflammation, C-reactive protein, clinical relevance, cardiovascular risk
